pMP31-1 Citations (4)

Originally described in: Convergent evolution of escape from hepaciviral antagonism in primates.
Patel MR, Loo YM, Horner SM, Gale M Jr, Malik HS PLoS Biol. 2012;10(3):e1001282. doi: 10.1371/journal.pbio.1001282. Epub 2012 Mar 13. PubMed Journal

---

Articles Citing pMP31-1

Articles
Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon expression in intestinal epithelial cells. Ding S, Zhu S, Ren L, Feng N, Song Y, Ge X, Li B, Flavell RA, Greenberg HB. Elife. 2018 Nov 21;7. pii: 39494. doi: 10.7554/eLife.39494. PubMed
Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. Chao CC, Gutierrez-Vazquez C, Rothhammer V, Mayo L, Wheeler MA, Tjon EC, Zandee SEJ, Blain M, de Lima KA, Takenaka MC, Avila-Pacheco J, Hewson P, Liu L, Sanmarco LM, Borucki DM, Lipof GZ, Trauger SA, Clish CB, Antel JP, Prat A, Quintana FJ. Cell. 2019 Dec 12;179(7):1483-1498.e22. doi: 10.1016/j.cell.2019.11.016. Epub 2019 Dec 5. PubMed
Conserved Functions of Orthohepadnavirus X Proteins to Inhibit Type-I Interferon Signaling. Choonnasard A, Shofa M, Okabayashi T, Saito A. Int J Mol Sci. 2024 Mar 28;25(7):3753. doi: 10.3390/ijms25073753. PubMed
MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity. Liu Y, Hou D, Chen W, Lu X, Komaniecki GP, Xu Y, Yu T, Zhang SM, Linder ME, Lin H. Proc Natl Acad Sci U S A. 2024 Aug 20;121(34):e2403392121. doi: 10.1073/pnas.2403392121. Epub 2024 Aug 14. PubMed

If you have published an article using this material, please email us at to have your article added to this page.